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Infectious Disease

FDA Approves New Tuberculosis Drug: Bedaquiline (Sirturo®)
Megan Ruffner, fifth-year pharmacy student from Defiance, Ohio; Kent Wilin, fourth-year pharmacy student from Findlay,
Ohio; Charles Hay, fourth-year pharmacy student from Celina, Ohio; Zachary Crawford, fifth-year pharmacy student from
Centerville, Ohio; Andrew Roecker, PharmD '00, BCPS, professor of pharmacy practice

This knowledge-based activity is targeted for all pharmacists
and is acceptable for 1.0 hour (0.1 CEU) of continuing
education credit. This course requires completion
of the program evaluation and at least a 70 percent grade
on the program assessment questions.

ACPE Universal Activity Number (UA.i"\l): 0048-0000-13-176-HO 1-P
Objectives
After completion of this program, the reader should be able
to:
1. Describe the pathophysiology of tuberculosis.
2. Evaluate the need for new drug therapies in the
treatment of multi drug-resistant tuberculosis.
3. Explain the mechanism of action of bedaquiline.
4. List the major side effects of bedaquiline.
5. Discuss how bedaquiline will positively impact
current therapy.
Abstract
Tuberculosis (TB), caused by the acid-fast bacilli (AFB) Mycobacterium tuberculosis, is an infectious disease that con·tinues to greatly impact morbidity and mortality worldwide;
in 2011 it caused 1.4 million deaths. Some strains of the bacteria have become resistant to current treatment regimens,
resulting in multidrug-resistant (MOR) and extensively drugresistant (XOR) TB. The emergence of these resistant strains
of bacteria calls for new treatment regimens that can quickly
and effectively eradicate the organism. The U.S. Food and Drug
Administration (FDA) recently approved Sirturo® (bedaquiline)
with the indication of MDR pulmonary TB. Bedaquiline introduces a novel mechanism of action via the inhibition of bacterial adenosine triphosphate (ATP) synthase. In this article
we will further explore the background information for TB,
current treatment regimens, adverse effects of bedaquiline
and studies that explore the place for bedaquiline in the
treatment of TB.
Introduction
Tuberculosis, causeCi by Mycobacterium tuberculosis, remains a prevalent disease globally with approximately one
third of the world's population infected.1 According to the
Centers for Disease Control and Prevention (CDC), 10,528
cases of TB were reported in the United States in 2011,
which is a 5.8 percent decrease from the number of cases
reported in 2010. However, the World Health Organization
(WHO) estimates that in 2011 there were 8.7 million new
cases and 1.4 million deaths from TB worldwide.2 Tuberculosis is a major consideration for human immunodeficiency
virus (HIV) infected patients, being the leading killer of this
population. This shows that while TB is on the decline in the
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United States, the vast impact on worldwide incidence and
mortality remains a concern.
Mycobacterium tuberculosis is transmitted via inhalation of
droplets in the air and typically infects the lungs when active.3 Tuberculosis can be latent or active in an individual.
Latent TB occurs when a healthy individual inhales the organism, the lungs allow the organism to enter the body via
macrophages and the lymphatic system, but the body does
not allow the bacteria to actively grow.3.4 Patients with latent
TB will not feel ill or be contagious; however, a latent infection may become active if an individual's immune system
becomes compromised. Active TB presents with symptoms
such as severe cough, chest pain, hemoptysis, fatigue and
fever. Individuals that are immunocompromised, such as
those with HIV infection, are at increased risk of developing
the active infection.
A Mantoux tuberculin skin test may identify, but not differentiate, both latent and active TB; a chest x-ray and AFB smear
can confirm an active infection.s.6 Tuberculosis is an AFB,
rendering it impossible to identify via gram stain, and requiring identification via special AFB smears.3 Culturing of a sputum sample must be done to test the specimen for susceptibility to drug regimens.
To avoid producing resistant strains of TB and to ensure
complete eradication of the organism, it is recommended to
use multiple agents when treating active TB.6 Despite such
precautions, MOR TB and XOR TB continue to present an
obstacle in treatment. MOR TB is defined as being resistant
to the drugs isoniazid and rifampin; this presents an obstacle
to treatment because these are two drugs commonly used to
treat TB.7 Extensively drug-resistant TB is resistant to these
two drugs as well as any fluoroquinolone and any of the injectable second-line drugs for TB, such as amikacin or kanamycin. Research and development of new drugs to treat TB
are needed for multiple reasons including shortening the
duration of treatment regimens and improving treatment of
MOR and XOR TB.6
Current Treatment
The American Thoracic Society, CDC, and the Infectious Diseases Society of America (IDSA) have partnered to publish
treatment guidelines for TB in the United States.6 For drug
susceptible strains of TB, an initial treatment regimen of
ethambutol (EMB), isoniazid (!NH), rifampin (RIF), and
pyrazinamide (PZD) for two months is recommended followed by a maintenance treatment of six to nine months using various combinations of the same drugs. If drug resistant
forms of TB develop during treatment, at least two or three
new drugs should be added to the regimen in replacement of
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TubercuJosis. 6

Drug Combination

Frequency and Duration

Options for Continuation*

!NH, RIF, PZA, EMB

7 days/week for 8 weeks or
5 days/week for 8 weeks

1,2,3

!NH, RIF, PZA, EMB

7 days/week for 2 weeks then twice weekly for 6 weeks or
5 days/week for 2 weeks then twice weekly for 6 weeks

2,3

!NH, RIF, PZA, EMB

3 times weekly for 8 weeks

4

!NH, RIF, EMB

7 days/week for 8 weeks or
5 days/week for 8 weeks

5

*Referenced in Table 2

Table 2. Options for Continuation Phase of Drug Susceptible Tuberculosis. 6

Option#

Drug Combination

Frequency and Duration

1

INH/RIF

7 days/week for 18 weeks or
5 days/week for 18 weeks

2

INH/RIF

Twice weekly for 18 weeks

3

INH/RPT*

Once weekly for 18 weeks

4

INH/RIF

Three times weekly for 18 weeks

5

INH/RIF

7 days/week for 31 weeks or
5 days/week for 31 weeks or
Twice weekly for 31 weeks

*RPT (rifapentine)

the agents to which resistance has been acquired. These
drugs should be selected based upon susceptibility testing
and may include drugs such as streptomycin, amikacin, kanamycin, p-aminosalicylic acid, or a fluoroquinolone.
The current treatment regimen, as described above, presents
multiple obstacles to optimal treatment of TB. 1 The high pill
burden along with the duration of treatment of at least six
months leads to patient noncompliance. Direct observation
therapy has been implemented to avoid this issue, but is expensive and time-consuming. The current first-line treatment regimen presents many potentially severe side effects,
such as hepatotoxicity and permanent visual impairment.a
Rifampin decreases the concentrations of protease inhibitors, which are a class of drugs used to treat HIV infection;
the common presence of HIV and TB as comorbidities presents a treatment dilemma. These are a few of the foremost
reasons why new drugs for TB are desperately needed. The
potential impact of bedaquiline on TB treatment and these
treatment obstacles will be explored throughout the remainder of the article.
Development
Bedaquiline (Sirturo®) was approved on December 28, 2012,
by the FDA for MDR pulmonary tuberculosis after going
through the FDA's priority review and has received orphanMay 2013 Volume 4, Issue 2

product designation. 9 Fast tracking this medication has made
it available to patients sooner but comes with less substantial
data than is usually seen with a newly marketed drug. The
accelerated approval of bedaquiline allowed it to be placed
on the market with data that show it is reasonably likely to
provide clinical benefits to patients. Janssen Therapeutics
(the manufacturer of bedaquiline) will continue to conduct
studies to confirm the drug's effectiveness and safety.
Mechanism of Action
Bedaquiline is of the diarylquinoline class of drugs and has
been seen to act through inhibition of bacterial ATP synthase
by inhibiting the c subunit of the enzyme.10 Bedaquiline contains two chiral centers giving the molecule several possible
stereoisomers, of which the (R,S) configuration has been
seen to be the most active against TB. This stereoselectivity
is indicative of specific binding to a target protein. Through
gel electrophoresis of two eluted proteins from an affinity
column, the ATP subunits were identified as the target. Further testing with a BIAcore carboxymethyl-Sepharose chip
identified ATP synthase subunit c as the primary target for
bedaquiline. Current treatments target cell wall synthesis,
ribonucleic acid (RNA) transcription, and pH levels of the
environment (isoniazid and ethambutol, rifampin, and pyrazinamide respectively). The novel method of targeting ATP
synthase with bedaquiline allows for use against resistant TB
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and latent TB by depleting the bacterium's energy supplies.
An extensive target study by Haagsma et al. has confirmed
the action of bedaquiline takes place at the c subunit of ATP
synthase, specifically at the interface between subunits a and
c to block conformational changes in ATP synthase. The
study also shows that bedaquiline does not compete with
protons for a common binding site and, thus, is not affected
by proton motor force like such drugs as sodium azide and
other ATP synthase inhibitors which increases the efficacy of
bedaquiline. Bedaquiline, however, is dependent upon electrostatic attractive forces that bind subunit c.11 It was seen
that as sodium chloride concentrations increased in the
body, bedaquiline binding affinity decreased. It is also noteworthy to include that bedaquiline's activity is not affected
significantly by pH changes in the range from 5.25 to 7.5.
This is advantageous due to the acidic environment of the
lung where latent TB can often be found but is extremely
difficult to treat.

line liver enzymes and serum electrolyte levels should be
recorded in case there is a need for compensation during
therapy. The second FDA black box warning alerts health
care providers that in trials bedaquiline was associated with
a higher risk of death compared to placebo. 14 In one of the
clinical trials that led to bedaquiline's approval, the number
of deaths in the treatment group was statistically significantly higher than the placebo group; however, all of the placebo deaths and roughly half of the bedaquiline deaths
"seemed to be related to tuberculosis."16 The black box warning instructs health care providers to only use bedaquiline "if
no other effective treatment regimen is available."14 This
black box warning truly demonstrates why bedaquiline is
reserved for those patients who have no other options. The
early approval of a drug with such a warning demonstrates
the urgent need for effective treatment of MOR TB. Janssen
will be distributing educational material with the medication
to ensure the drug is used appropriately.16

Unique Features
Bedaquiline has shown to be a viable drug for targeting latent mycobacteria. Its novel mechanism of action provides
another option for treatment in MDR TB, which by definition
is resistant to the more familiar mechanisms of action.1 2 Researchers found that dormant mycobacteria have active and
functional ATP synthase. Depleting ATP in the dormant bacteria by bedaquiline mediated inhibition of ATP synthase
leads to bactericidal activity. Researchers also found that
bedaquiline was slightly more effective in dormant bacilli
compared to replicating bacilli, while the present first and
second-line TB antibiotics exhibited strong bactericidal activity on replicating mycobacteria but not on the dormant bacilli. This unique feature of bedaquiline could reduce the time
needed to treat infection when used in combination with
current first and second-line therapies. Bedaquiline was seen
to be effective at a dose of 400 mg at days 4 through 7 in an
early bactericidal activity study by Rustomjee.13 This study
suggests that bedaquiline could be used as a sterilizing agent
in current TB regimens because of the drug's ability to deplete mycobacterium energy stores.

The most common patient-reported side effects are nausea,
painful or stiff joints, headache, chest pain and hemoptysis.14
These adverse events fall within the mild to moderate range,
and only nausea has been reported statistically as significantly higher than placebo.17 As a major substrate for
CYP3A4, bedaquiline should be administered with caution
with drugs that induce or inhibit CYP3A4. Bedaquiline should
also not be administered with alcohol, ivabradine, mifepristone, St John's Wort or tocilizumab.14 Also, it is important
that health care providers monitor patients' liver function. If
aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevations last for longer than two weeks, it is
advised that therapy should be stopped. Through animal
studies, bedaquiline has been rated at pregnancy risk factor B.

Adverse Effects
When used in the appropriate situation, bedaquiline offers
health care providers and patients with another weapon
against MOR TB; however, it is important to note that use of
bedaquiline has been associated with serious adverse events
that warrant attention and monitoring. The FDA has placed
two black box warnings on bedaquiline. The first warns that
patients may experience QT prolongation. The concern with
QT prolongation is the increased risk of the development of
arrhythmias, especially torsade de pointes. 14 Torsade de
pointes is a ventricular arrhythmia that is life threatening
and has specifically been linked to QT prolongation.is Other
risk factors that increase the risk of adverse outcomes from
QT prolongation include uncompensated heart failure, low
serum electrolyte levels and hypothyroidism. Because of bedaquiline's possible effect on QT prolongation, it is recommended that an electrocardiogram be recorded at the beginning of therapy and at weeks 2, 12, and 24.14 If an arrhythmia
develops, therapy should be discontinued. Additionally, base-
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Literature Review
The diarylquinoline TMC207 for multidrug-resistant tuberculosis.22·23
As part of the phase 2 trials for bedaquiline, Diacon et
al. performed a double-blind, randomized placebo-controlled
study in South Africa. Eligible study participants had confirmed MDR TB and received either placebo (24 patients) or
bedaquiline 400 mg (23 patients) once daily for weeks 1 and
2, followed by 200 mg three times a week for weeks
3 through 8 along with a preferred background regimen of
kanamycin, ofloxacin, ethionamide, pyrazinamide, and cycloserine or terizidone (modifications could be made following susceptibility testing or adverse events). After the eight
weeks of study medication, participants continued the background medication regimen only and were followed for a
total of two years. Administration of each dose of study
medication was supervised to ensure compliance. The
authors reported results after eight weeks and also at two
years. Outcomes were measured via sputum samples
cultured in a liquid broth medium (MGIT system) before
treatment initiation and weekly thereafter during study
medication administration.
Quantitative serial sputum
colony counting was also performed. Blood samples were
monitored for plasma levels ofbedaquiline.
In the literature published at eight weeks, the authors con-
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Table 3. Common Adverse Effects of Conventional TB Therapy Compared To Bedaquiline. 9,rn-21
Ethambutol

Isoniazid

Rifampin

Pyrazinamide

Bedaquiline

Cardiovascular

Myocarditis

Hypertension,
tachycardia

Edema, flushing

x

Chest pain,
Black box
warning
for QT
prolongation

CNS

Confusion,
hallucinations,
headache

Depression,
fatigue, fever,
headache

Ataxia,
headache

Fatigue

Headache

Endocrine

Acute gout

Gynecomastia,
hyperglycemia,
metabolic
acidosis

Adrenal
insufficiency

Gout (rare)

x

Gastrointestinal

Anorexia, nausea/
vomiting

Anorexia, nausea/vomiting

GI upset

Anorexia, nausea/
vomiting

Anorexia, nausea/vomiting

Hematological

Anemia,
leukopenia,
thrombocytopenia

Agranulocytosis,
anemia

Agranulocytosis
anemia,
leukopenia,
thrombocytopenia

Thrombocytopenia
(rare)

x

Hepatic

Elevated liver
enzymes and
toxicity

Black box
warning
for hepatitis

Increase liver
enzymes (rare
hepatitis)

Dose related
hepatotoxicity
(rare) Fever

Increase liver
enzymes

Neuromuscular

Peripheral
neuropathy

Dose related
peripheral
neuropathy

General numbness

Myalgia

Arthralgia

Ocular

Impairment of
color vision
(inflammation of
optic nerve)

Blurred vision

x

x

x

x

x

Renal

Nephritis

x

Elevations in BUN
and uric acid leading to potential
renal failure

Respiratory

Pneumonitis

x

x

x

Hemoptysis

Miscellaneous

x

Lupus-like
syndrome

x

x

x

eluded that taking bedaquiline resulted in crucial timedependent bactericidal activity. The bedaquiline group had
quicker conversions to a negative sputum culture (hazard
ratio 11.8, 95 percent confidence interval: 2.3 to 61.3). In the
eight weeks, 48 percent of the treatment group converted to
a negative culture, while 9 percent of the treatment group
did. Log10 colony forming units (CFU) declined more rapidly
in the treatment group. At eight weeks, and also at two years,
nausea was the only side effect that appeared significantly
more in the treatment group than the placebo group. In the
two year follow-up article, the authors noted that 50 percent
May 2013 Volume 4, Issue 2

culture conversion for the treatment group occurred at 78
days, while this occurred at 129 days in the placebo group;
this again demonstrates the advantageous time-dependent
activity of bedaquiline. After two years, it was also seen that
more patients receiving placebo (4/18) than treatment
(0/16) that were initially susceptible to ofloxacin developed
resistance to it; suggesting bedaquiline lowers the risk of
acquiring additional drug resistance throughout therapy.
This study shows that bedaquiline may be an important drug
for reducing time for treating MDR TB and may potentially
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decrease the incidence of newly formed resistance during
treatment. Although the study was well designed, the small
sample size (47 patients) is a limitation to the external validity of the study. Due to this, larger trials investigating more
safety aspects of the drug are needed to determine the future
place for this new drug in the TB guidelines.
14-day bactericidal activity of PA-824, bedaquiline,
pyrazinamide, and moxifloxacin combinations: a randomized trial.24
Diacon et al. performed a phase 2A, partially double-blinded,
randomized trial to assess early bactericidal activity (EBA),
safety, tolerability, and pharmacokinetics of various combinations of various TB drugs (Table 4). This study was designed recognizing the need for shorter and better tolerated
regimens needed to treat TB worldwide.

between treatment groups and the control.
The results showed that the mean 14 day EBA of PA-824,
moxifloxacin, and pyrazinamide was 0.233 [SD 0.128], which
was higher than any other group. The other groups were bedaquiline at 0.061 [0.069]; bedaquiline and pyrazinamide at
0.131 [0.102]; bedaquiline and PA-824 at 0.114 [0.050]; PA824 and pyrazinamide at 0.154 [0.040], and rifafour e-275 at
0.140 [0.094].
The authors conclude that bedaquiline/PA-824 and PA-824/
pyrazinamide/moxifloxacin showed activity comparable
with that of current standard treatment and thus may be
studied further as building blocks of future front line regimens. There is currently a trial sponsored by the Global Alliance for TB Drug Development exploring the combination of
bedaquiline, PA-824, clofazimine, and pyrazinamide for EBA
activity. 24

Patients were from two outpatient clinics in South Africa and
included if they were otherwise relatively healthy and had
confirmed fully drug susceptible TB. Bedaquiline and PA824, a nitroimidazo-oxazine in the pipeline, were the new
agents included in the study and were chosen based upon
their synergism with pyrazinamide in murine experiments.
Rifafour e-275 was used as the control in the study, representing current standard treatment. Rifafour e-275 contains
isoniazid 75 mg, rifampicin 150 mg, pyrazinamide 400 mg,
and ethambutol 275 mg; patients received two (30-37 kg),
three (38-54 kg), or four (55-70 kg) a day based on body
weight. Experimental group dosing is described in Table 4.
Fifteen patients were included in each study group and 10
patients were included in the control group.

Safety, tolerability, and pharmacokinetic interactions of
the antituberculosis agent TMC207 (bedaquiline) with
efavirenz in healthy volunteers: AIDS clinical trials
group study A5267.25
In April 2012, Dooley et al. published a study in the Journal
of Acquired Immune Deficiency Syndrome that examined the
pharmacokinetic related interaction of bedaquiline therapy
alone, as well as in conjunction with the HIV medication
efavirenz. The rationale behind this study was that roughly
15 percent of patients infected with TB also suffer from HIV.
This study is important because it also investigates the pharmacokinetic properties of bedaquiline monotherapy.

The primary outcome of the study was the 14 day early bactericidal activity (EBA) of each combination based upon the
daily fall in CFU per mL of sputum measured via log10 CFU;
sputum sample were collected daily overnight. Safety monitoring included daily vital signs and physical examination as
well as 12-lead electrocardiogram (ECG) on days 1, 3, 8, and
14. After the two weeks, patients were referred to local TB
clinics for a standard course of therapy and returned for
study follow-up visits at 14, 28, and 90 days after study completion. The study was not powered to compare differences

Conducted in the United States, this phase 1 trial consisted of
healthy individuals 18 to 65 years in age. Notable exclusion
criteria included positive HIV antibody test, elevated hepatic
enzymes, below average hemoglobin, white cell count, or
platelets, irregular ECG, estimated creatinine clearance below 50 mL/min, or any indication of possible TB infection.
Additionally, "women of reproductive potential" and current
users of a prescription drug known to inhibit CYP3A were
excluded. To begin the study, participants were given a single
400 mg dose of bedaquiline. Plasma levels of bedaquiline and

Table 4. Treatment Group Regimen Description. 2 4

Treatment
Group

Bedaquiline
Day 1- 700 mg
Day 2- 500 mg
400 mg daily thereafter

Pyrazinamide
Placebo
Daily

1

x

x

2

x

3

x

PA-824
200 mg daily

Pyrazinamide
2 5 mg/kg daily

Rifafour
e-275

x
x

4

x

x

5

x

x

x
x

Control

36

Moxifloxacin
400 mg daily
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one of its metabolites (M2) were measured l, 2, 3, 4, 5, 6, 8,
12, 24, 48, 72, 120, 168, 216, 264, and 336 hours after the
dose. This was designated period 1. Over the next 14 days,
participants received 600 mg of efavirenz nightly. On day 28
of the trial (day 14 of efavirenz therapy) the participant's
efavirenz plasma levels were drawn 1, 2, 3, 4, 8, 12, and 24
hours postdose. The following day, 400 mg of bedaquiline
was again administered to participants in addition to the
continuation of 600 mg efavirenz nightly. Plasma bedaquiline/M2 levels were collected per the same schedule as period 1.
At the end of the study the researchers compared the area
under the curve (AUC), maximum concentration (Cmax), time
to maximum concentration (T max), and half-life (tv,) of bedaquiline and M2 as a monotherapy and compared these values to the ones taken when efavirenz was administered concomitantly. Of statistical relevance, efavirenz was found to
decrease the AUC of bedaquiline by about 20 percent. It is
important to note though, that the participants' bedaquiline
levels were still therapeutic. Additionally, it increased the
Cmax of M2; however, the AUC of M2 was unchanged. This correlates to an increased clearance of M2 in the presence of
efavirenz. While this study addressed a key consideration in
the treatment of MDR TB, it is only a beginning. Dooley et al.
achieved a power above 80 percent. While this is commendable, they still only used a small sample size of healthy volunteers. A much larger study needs to be conducted that targets
a population similar to the patients for whom bedaquiline is
intended .2 s

4.

5.

6.

7.

8.

9.

10.

11.

12.

13.

14.

Conclusion
Worldwide, tuberculosis is the second highest cause of death
from an infectious disease.17 Of those patients who are currently infected with tuberculosis, 35.3 percent of the newly
diagnosed patients have a MDR strain, while 76.5 percent of
previously treated patients have a MDR strain. These statistics alone demonstrate the importance of bedaquiline and
other new TB drugs. While bedaquiline is currently only approved for MOR TB, some early studies show potential for
this drug to be included in the early phase of future treatment regimens to reduce the total time of treatment; this in
turn would have a positive impact on patient compliance.
Also, it appears as if bedaquiline could be important in the
treatment of patients with both TB and HIV; this is shown by
the small impact of efavirenz on bedaquiline levels as noted
above in the literature review. Though there are serious adverse events associated with bedaquiline therapy, health
care professionals must weigh these risks against the fact
that there are not many options for patients with MOR TB.
When used appropriately, bedaquiline can offer some help to
patients suffering from this tenacious disease.
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Assessment Questions
1.

2.

Tuberculosis (TB) is an important consideration for
patients with
since it is the leading cause
of mortality in this population.
A. Diabetes mellitus
B. HIV
C. Hypertension
D. Sleep apnea
TB most commonly infects which part of the body?
A. Heart
B. Liver
C. Skin and soft tissue
D. Lungs

3.

Multidrug-resistant (MOR) TB is defined as:
A. TB that no longer responds to any medications
8. TB that is resistant to a fluoroquinolone
C. TB that is resistant to isoniazid and rifampin
D. TB that responds well to first-line treatment
options

4.

Which of the following is NOT a reason for using multiple
medications in a regimen for treating active TB?
A. To avoid resistance development
B. To ensure complete eradication of the organism
C. To attack the organism with multiple
mechanisms of action
D. To make sure the dose of one particular
medication is not too high for tolerance of
side effects

5.

Which of the following is a potential benefit of including
bedaquiline in an MDR TB regimen?
A. Reducing total time of treatment
8. Allowing a single medication to be used for the
treatment of active TB
C. Availability in a wide variety of dosage forms
D. None of the above are benefits ofbedaquiline
treatment

8.

Bedaquiline has shown to be a viable drug for targeting
latent mycobacteria.
A. True
B. False

9.

Bedaquiline contains a black box warning for which side
effect?
A. Hepatotoxicity
B. Gastrointestinal bleeding
C. QT prolongation
D. None of the above

10. Prior to bedaquiline therapy, which patient-specific

baseline levels should be measured?
A. Liver enzymes
B. ECG
C. Serum electrolytes
D. All of the above

To receive continuing education credit for this program, you
must answer the above questions and fill out the evaluation
form. Please visit www.onu.edu/pharmacy to enter the
required information. Please allow two to three weeks for
electronic distribution of your continuing education certificate, which will be sent to your valid email address in PDF
format.

6. What is the primary target for bedaquiline?
A. Cell wall synthesis
B. ATP synthase
C. RNA transcription
D. pH levels

7.
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Bedaquiline is affected by which of the following?
A. Electrostatic attractive forces
B. Proton motor force
C. pH from 5.25 - 7.5
D. All the above
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To receive continuing education credit for this program, visit www.onu.edu/pharmacy/CE OR fill out the form below
including your indicated answers to the assessment questions and return to:
Office of Continuing Education at the Raabe College of Pharmacy
Ohio Northern University
525 South Main Street
Ada, Ohio 45810

Program Title:

FDA Approves New Tuberculosis Drug: Bedaquiline (Sirturo®)
UAN: 0048-0000-13-176-HOl-P CEUs: 0.1

All information must be printed CLEARLY to ensure accurate record keeping for attendance and the awarding of
continuing education credit. Certificates will be distributed as a PDF document to a valid email address.
Name:
Address:
City:

State:

Phone:

Email:

Pharmacy License #:

State:

Zip:

y

ONU Alumni?

N

1

2

3

4

5

Describe the pathophysiology of tuberculosis.

1

2

3

4

5

Evaluate the need for new drug therapies in the treatment of
multidrug-resistant tuberculosis.

1

2

3

4

5

Explain the mechanism of action of bedaquiline.

1

2

3

4

5

List the major side effects of bedaquiline.

1

2

3

4

5

Discuss how bedaquiline will positively impact current therapy.

1

2

3

4

5

The program met your educational needs.

1

2

3

4

5

Content of the program was interesting.

1

2

3

4

5

Material presented was relevant to my practice.

1

2

3

4

5

The program objectives were clear.
The program met the stated goals and objectives:

Comments/Suggestions for future programs:

Thank you!
Answers to Assessment Questions-Please Circle Your Answer
1.ABCD

4.

A B C D

7.

A B C D

2.

A B C D

5.

A B C D

8.

A B

3.

A B C D

6.

A B C D

9.

A B C D

Any questions/comments regarding this continuing education program can
be directed to Lauren Hamman, Advanced Administrative Assistant for the
Office of Continuing Education (email: 1-hamman,c onu.edu, phone 419772-2280).

10. A B C D

Ohio Northern University is accredited by the
Accreditation Council for Pharmacy Education as a
provider of continuing pharmacy education. This
program is eligible for credit until 05/16/16.

